However, progress faces challenges such as fragmented data efforts, lack of consensus on biomarkers and regulations, limited involvement from traditional pharma investors, and insufficient clinician training in healthspan science.

While progress is ongoing, it remains slow, but the report suggests that with stronger leadership, coalition-building, and strategic investments, the field could accelerate significantly toward impactful breakthroughs.

A recent report from the McKinsey Health Institute underscores the urgent need to accelerate progress in healthspan science to promote healthier aging, highlighting seven critical shifts to advance longevity biotech.

These seven key shifts involve establishing clear definitions of the field, advancing scientific understanding, developing standardized biomarkers, improving clinical trial design, clarifying regulatory pathways, attracting investment, and expanding clinical expertise.

If these efforts succeed, there is potential to add up to 45 billion years of higher-quality life in the next decade, with addressing age-related diseases offering enormous economic benefits given they account for about a third of the global disease burden.

The report advocates for global collaboration, innovative funding models, and integrating healthy longevity into mainstream healthcare to unlock the full potential of aging interventions.